Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depression: Overview01:18

Depression: Overview

242
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
242
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

85
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
85
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

118
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
118
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

59
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
59
Long-term Depression01:05

Long-term Depression

30.9K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
30.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enlarged Centrum Semiovale Perivascular Spaces as a Noninvasive Imaging Marker of Vascular Amyloid Deposition in Amyloid-Positive Individuals without Cerebral Amyloid Angiopathy-Related Hemorrhages.

Dementia and geriatric cognitive disorders extra·2026
Same author

Evolution of the complication profile of AF ablation in the pulsed field era.

Journal of cardiology·2026
Same author

Delusional parasitosis with shared psychotic features secondary to vitamin B12 deficiency and mild cognitive impairment: a case report.

BMC psychiatry·2026
Same author

Plasma vitamin C levels are associated with brain structural networks on MRI: A large cohort study.

PloS one·2026
Same author

[Infection or Autoimmunity: Key Imaging Points for Differential Diagnosis].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same author

Microfluidic platforms for probing spontaneous functional recovery in hierarchically modular neuronal networks.

Communications engineering·2026

Related Experiment Video

Updated: Jun 30, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K

Fronto-striato network function is reduced in major depressive disorder.

Reoto Kijima1, Keita Watanabe2, Naomichi Okamoto1

  • 1Department of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan.

Frontiers in Psychiatry
|March 21, 2024
PubMed
Summary

Major depressive disorder (MDD) is linked to altered reward system function, particularly in younger patients. This study found no correlation between reward system changes and MDD symptom severity.

Keywords:
first episodemajor depressionprefrontal cortexreward systemstriatum

More Related Videos

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

10.6K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

49

Related Experiment Videos

Last Updated: Jun 30, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K
Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

10.6K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

49

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Imaging

Background:

  • Major depressive disorder (MDD) significantly impacts global quality of life and disability.
  • The brain's reward system, crucial for motivation and pleasure, is implicated in MDD pathophysiology.
  • Previous research explored the reward system network in MDD, but the relationship in drug-naïve, first-episode patients concerning specific symptoms and age remained unclear.

Purpose of the Study:

  • To investigate the relationship between the fronto-striato network (FSN), a key component of the reward system, and drug-naïve, first-episode MDD patients.
  • To examine the association of the FSN with detailed MDD symptoms and patient age.
  • To explore the interaction between age and MDD on the FSN.

Main Methods:

  • Enrolled 89 drug-naïve first-episode MDD patients and 82 healthy controls (HCs).
  • Analyzed the correlation between FSN and age, and the interaction between age and illness in FSN in subsets of MDD and HC groups.
  • Assessed the association between FSN and the 17-item Hamilton Rating Scale for Depression (HAMD-17) scores in MDD subjects.

Main Results:

  • Age was inversely correlated with FSN in HCs, but not in MDD patients.
  • FSN showed a significant interaction with MDD and age (p=1.04e-08), indicating age's effect on FSN differs in depression.
  • No correlation was found between FSN and total HAMD-17 scores or individual symptom scores.

Conclusions:

  • Reward system dysfunction, specifically within the FSN, is present in MDD patients.
  • The impact of age on FSN appears altered by the presence of depression, potentially affecting younger patients more.
  • FSN may serve as a biological marker for MDD, though age-related effects require careful consideration; symptom severity is not directly correlated.